HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells.
about
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical modelsHER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1BEpidermal Growth Factor Receptor Cell Proliferation Signaling PathwaysERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1)Targeting HER3 with miR-450b-3p suppresses breast cancer cells proliferation.Development and characterization of small bispecific albumin-binding domains with high affinity for ErbB3.HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cellsTargeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum.A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers.Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinibThe erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cellsHER2/HER3 regulates extracellular acidification and cell migration through MTK1 (MEKK4).Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic.A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy.HER3 as a Therapeutic Target in Cancer.The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.ErbB3 upregulation by the HNSCC 3D microenvironment modulates cell survival and growth.hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.SNP rs3202538 in 3'UTR region of ErbB3 regulated by miR-204 and miR-211 promote gastric cancer development in Chinese population.The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation.Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC.Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors.Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment.Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer
P2860
Q27853067-2DE1E891-A4D7-46EB-83C3-BBA947493519Q28551145-07BCDE5B-946E-40C8-B737-EB99B93608A0Q33737298-B27C5C83-79FE-4ECC-84D8-91C603332B40Q33772914-567AEA27-7EC3-4889-AFFC-38330EC1754FQ34036131-8A38399A-8308-43D3-BFD1-4BAE54D1E982Q34752052-C01A2770-CB93-4AC9-9B7C-A09144082998Q35201923-4C587580-F5C8-40FB-8E3D-4F71C1628E2CQ35890128-3F0A80EC-A981-47F5-BB1D-1FC26706A92BQ36359705-F7082CEE-439D-4172-93B6-4A3FAA46687FQ36562299-F198FFD2-A66E-4F63-8291-829B079DF65AQ36771985-57F3F5C2-A216-462F-B34D-30FDAAEEE100Q37407344-D074BF4E-5E4B-4E29-B261-3A6C71690333Q38214802-1D551BA6-2216-466E-B1E6-4A333ED912BEQ38238616-477A3FA0-64DC-4DDD-86D6-5E686337FB71Q38725101-270937E4-7F03-40DF-932C-5F0E84E90A81Q38766447-F9F17362-16D6-4BC5-B79E-BA921DC05962Q38864254-ECB545FB-33F6-48B5-BBA5-5F6423E4B6ADQ38876630-C4F8E065-101B-4D4B-B571-467670AC3E71Q41036589-89F9B11E-9D62-4833-B2A8-DABEBD7E1094Q41667670-97857A17-3DE4-4286-AC3C-BF5FA010A8F8Q42557873-FB9611CA-1173-4268-A8F4-C1D3C31A7955Q47782406-B6616A5B-C10C-44E1-AB96-358EA4EBB717Q55091931-FC7C5234-9AEF-4C18-A364-86EA004A7F87Q58112887-E64698A2-4358-4A9C-AB55-A204646DC849
P2860
HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
HER3 signalling is regulated t ...... s in HER2-driven tumour cells.
@en
HER3 signalling is regulated t ...... s in HER2-driven tumour cells.
@nl
type
label
HER3 signalling is regulated t ...... s in HER2-driven tumour cells.
@en
HER3 signalling is regulated t ...... s in HER2-driven tumour cells.
@nl
prefLabel
HER3 signalling is regulated t ...... s in HER2-driven tumour cells.
@en
HER3 signalling is regulated t ...... s in HER2-driven tumour cells.
@nl
P2093
P2860
P356
P1433
P1476
HER3 signalling is regulated t ...... s in HER2-driven tumour cells.
@en
P2093
Andrei Goga
Dhara N Amin
Lionel Lim
Mark M Moasser
Natalia Sergina
P2860
P304
P356
10.1042/BJ20120724
P407
P577
2012-11-01T00:00:00Z